# Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19

**Authors:** Urvi Ray, Antje Schulze Selting, Roshan Priyarangana Perera, Zhiqi Yang, Vladislav Lysenkov, Siri Göpel, Michael Bitzer, Madhuri S. Salker, Stephan Ossowski, Olaf Riess, Nicolas Casadei, Yogesh Singh

PMC · DOI: 10.3389/fimmu.2026.1720551 · Frontiers in Immunology · 2026-03-09

## TL;DR

Long COVID is linked to altered NK-cell gene activity, leading to persistent symptoms like fatigue and cognitive issues.

## Contribution

The study identifies dysregulated NK-cell gene expression as a novel mechanism in long COVID.

## Key findings

- LTCS patients show reduced systemic cytokine levels and depleted NK and NKT cells.
- scRNA-seq reveals transcriptional reprogramming in NK cells, including upregulated PDCD4 and CXCR4.
- Functional assays confirm reduced inflammatory capacity of NK cells in LTCS patients.

## Abstract

Long-term COVID-19 syndrome (LTCS) or “long COVID” is a debilitating post-viral condition affecting approximately 2%–8% of individuals after SARS-CoV-2 infection. It manifests typically ≥3 months post-infection with symptoms persisting for at least 2 months, including fatigue, pulmonary dysfunction, and cognitive impairment, in the absence of alternative diagnoses. The biological mechanisms underlying LTCS remain poorly defined, yet emerging evidence implicates immune dysregulation.

We profiled plasma antibodies and cytokines from healthy controls (HC, N = 66), convalescents (CONV, N = 24), and LTCS patients (N = 94), followed by multiparametric 14-color flow cytometry of PBMCs from HC (N = 9), CONV (N = 6), and LTCS (N = 23) participants. To gain mechanistic insight, we performed single-cell transcriptomic profiling (scRNA-seq) on PBMCs from HC (N = 8), CONV (N = 6), and LTCS (N = 32) individuals.

LTCS patients exhibited elevated anti-SARS-CoV-2 IgG (spike S1/RBD/N) titers compared with HC, but displayed significantly reduced systemic cytokine levels, including IFN-γ, TNF-α, IL-6, and IL-10. Flow cytometry revealed marked depletion of CD56+CD16+ NK cells and CD56+CD3+ NKT cells, accompanied by altered T-cell activation states. scRNA-seq confirmed NK type I cell loss and uncovered broad transcriptional reprogramming with upregulation of PDCD4, CHD1, CXCR4, and SLC7A5 and downregulation of TGFBR3, RIPOR2, and MBNL1. Gene set enrichment analyses indicated activation of circadian and translational programs and suppression of olfactory receptor, neurotransmitter receptor, and GABA-gated ion-channel pathways. Functional assays validated reduced NK-cell inflammatory capacity in LTCS participants.

LTCS is characterized by systemic cytokine attenuation and a quantitative and functional NK-cell deficit coupled to neurosensory pathway suppression. These findings identify NK cells as key sentinels of LTCS pathophysiology and highlight an NK-centric neuroimmune axis as a promising target for biomarker discovery and therapeutic intervention.

Illustration showing two human profiles labeled “Long COVID” pointing to a cluster of cells, with arrows indicating decreased sensor gene expression, decreased cell fraction, and increased exhaustion and chromatin modulation.

## Linked entities

- **Genes:** PDCD4 (programmed cell death 4) [NCBI Gene 27250], CHD1 (chromodomain helicase DNA binding protein 1) [NCBI Gene 1105], CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852], SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140], TGFBR3 (transforming growth factor beta receptor 3) [NCBI Gene 7049], RIPOR2 (RHO family interacting cell polarization regulator 2) [NCBI Gene 9750], MBNL1 (muscleblind like splicing regulator 1) [NCBI Gene 4154]

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CHD1 (chromodomain helicase DNA binding protein 1) [NCBI Gene 1105] {aka CHD-1, PILBOS}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, MBNL1 (muscleblind like splicing regulator 1) [NCBI Gene 4154] {aka EXP, MBNL}, PDCD4 (programmed cell death 4) [NCBI Gene 27250] {aka H731}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TGFBR3 (transforming growth factor beta receptor 3) [NCBI Gene 7049] {aka BGCAN, betaglycan}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}
- **Diseases:** SARS-CoV-2 infection (MESH:D000086382), inflammatory (MESH:D007249), immune dysregulation (OMIM:614878), LTCS (MESH:D000094024), fatigue (MESH:D005221), NK type I (MESH:D006969), infection (MESH:D007239), pulmonary dysfunction (MESH:D011660), cognitive impairment (MESH:D003072)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13006230/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13006230/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC13006230/full.md

---
Source: https://tomesphere.com/paper/PMC13006230